Your LDL/ApoB Is Low. Are You Actually Safe?

We’ve all heard some version of the story.

Someone is lean. Active. Maybe they have been a runner or cyclist for years. Their LDL was normal.

Then they have a heart attack.

It feels random. But as we covered in Edition #022, normal LDL alone does not prove low cardiovascular risk. ApoB can tell a different story, and blood pressure, smoking, glucose, kidney health, Lp(a), family history and existing plaque can all change the picture.

Edition #024 covered what to do when LDL/ApoB remains high. This week starts after that job succeeds.

Suppose your LDL-C and ApoB are now appropriately low for your level of risk. Your PREVENT score is low. Your other major risk factors look good.

Are you finally safe?

A blood test is a snapshot. Atherosclerosis is built over time.

In pooled data from 18,288 people across four U.S. cohorts, cumulative LDL exposure from young adulthood through middle age predicted later coronary heart disease even after researchers adjusted for the most recent LDL measurement. [1]

That means two people with the same LDL and ApoB today may not have the same history. Someone who spent decades with low atherogenic exposure is different from someone who spent decades high and lowered it at 55.

But this is not an argument to stop once the number comes down. Lowering ApoB now reduces future exposure. If diet, exercise, medication or weight loss got you there, maintaining those interventions is part of keeping the risk low.

Not zero.

But “not zero” is very different from “high.”

A 2026 pooled primary-prevention study followed 16,384 adults without cardiovascular disease who were not taking lipid-lowering medication at baseline. Over a median 18.8 years, people with LDL-C below 70 mg/dL did not have significantly lower adjusted ASCVD risk than those at 70–99 mg/dL, while higher LDL, non-HDL cholesterol and ApoB were associated with more risk. [2]

That is observational evidence, not proof that lowering LDL below 70 has no benefit. It suggests something narrower: moving an elevated atherogenic burden into a favorable range matters more than assuming every additional drop must buy the same benefit in an already low-risk person.

A low PREVENT score follows the same principle. It means low predicted risk, not immunity.

Some people do.

A strong family history of premature heart disease, years of previously high ApoB/LDL, known plaque, smoking, hypertension, diabetes, kidney disease, chronic inflammatory disease or very high Lp(a) can change the picture.

Lp(a) deserves special mention. In a participant-level analysis of six statin trials, elevated Lp(a) remained associated with higher ASCVD risk even among people who had achieved low LDL levels. [3]

That analysis was funded by Novartis and several authors had industry relationships, so I would not use it alone. But it fits broader evidence and current guidelines, which recommend measuring Lp(a) at least once and using a high result as a reason to manage the other modifiable risks more aggressively. [4]

There is also a useful reality check. In September, Novartis reported that pelacarsen substantially lowered Lp(a) in its Phase III Lp(a)HORIZON trial but did not significantly reduce the combined outcome of cardiovascular death, heart attack, stroke or urgent coronary revascularization. [5]

So for now: know your Lp(a). Use it as risk context. Do not assume that chasing the number itself is already a proven strategy for preventing heart attacks and strokes.

Coronary artery calcium, or CAC, can add useful information when the treatment decision is uncertain.

In a 2026 MESA analysis, people with a PREVENT-ASCVD risk below 3% had event rates of about 1.1 per 1,000 person-years when CAC was zero versus 3.0 when CAC was present. [6]

That is a meaningful difference, but both groups were still low in absolute terms. CAC was most useful when treatment decisions were uncertain, especially near borderline-risk thresholds.

What about “soft plaque” that CAC misses?

Coronary CT angiography, or CCTA, can detect noncalcified plaque. In SCAPIS, 5.5% of asymptomatic people with CAC=0 had plaque on CCTA. In the Miami Heart Study, it was 16%. [4]

That sounds like a reason to scan everyone. It is not.

Finding more abnormalities is not the same as proving that screening improves outcomes. A 2026 systematic review of clinical guidelines found that routine imaging for asymptomatic coronary disease is not recommended. CAC is used mainly in selected cases where risk or treatment decisions remain uncertain, while routine CCTA screening lacks proven clinical benefit. [7]

Current U.S. guidance similarly reserves CCTA mainly for selected people expected to have more noncalcified plaque, such as some people with diabetes, HIV or inflammatory disorders. [4]

Inflammation matters. But population matters too.

A 2026 meta-analysis found that higher residual inflammation was associated with more cardiovascular events after treatment. The catch: these were 13,604 people who already had coronary artery disease and had undergone PCI. [8]

That is not the same population as an asymptomatic person with low PREVENT risk, controlled ApoB and no known cardiovascular disease.

So hsCRP can be useful when there is a reason to clarify inflammatory risk. It does not follow that every low-risk person should serially optimize hsCRP, NMR/LDL-P particle testing, small dense LDL, LDL particle size, advanced lipoprotein fractionation, oxidized LDL, oxidative-stress markers or whatever biomarker comes next.

Some of those tests can answer specific questions. That does not make them part of the minimum-effective stack once ApoB and the major risks are already well characterized.

If LDL/ApoB is appropriately controlled, PREVENT risk is low, blood pressure is controlled, you do not smoke, metabolic and kidney health are favorable, Lp(a) is known, and there is no specific history or finding suggesting higher risk, more testing should have to earn its place.

Will the result change what you do?

If yes, it may be worth getting.

If no, you may simply be measuring smaller pieces of risk that you cannot meaningfully act on.

If you can comfortably afford additional testing, understand its limitations and downsides, and not knowing creates more stress than knowing, going beyond the minimum can still be a reasonable personal choice. It just becomes optional rather than part of the minimum effective dose.

Low LDL/ApoB does not make cardiovascular risk disappear. Neither does a low PREVENT score or CAC of zero.

But once the major proven risks are controlled, finding ever-smaller pieces of residual risk does not automatically improve health.

More information is worth pursuing when it could change what you do. Testing simply because some theoretical risk must still exist is where optimization starts becoming Noise.

CONTROL: Keep LDL/ApoB appropriately low for your level of risk. Keep blood pressure, metabolic and kidney health favorable, do not smoke, and keep the other major modifiable risks controlled.

KNOW: Measure Lp(a) once. Know your family history and previous risk-factor history.

INVESTIGATE WHEN IT MATTERS: Use CAC or deeper evaluation when the result could reasonably change prevention or treatment. Symptoms and major risk enhancers are different from curiosity-driven screening.

MAINTAIN: Keep doing the diet, exercise, medications and other interventions that produced the favorable numbers.

STOP ESCALATING AUTOMATICALLY: Do not assume good standard risk assessment must lead to CCTA, repeated imaging, serial inflammatory markers or increasingly obscure cardiovascular panels.

Do not confuse “nothing more to optimize” with “nothing more to maintain.”

This article is for education, not individual medical advice. Do not start, stop or change a prescription medication based on this article. Discuss treatment decisions, supplements and medication changes with your clinician, especially if you have known cardiovascular disease or other medical conditions.

Subscribe free - one edition in your inbox every Wednesday. No spam. No conflicts of interest. Any future sponsorships will be clearly disclosed and personally vetted.

After subscribing, check your junk/spam folder for the confirmation email and mark it as ‘Not Spam’ to ensure delivery.

1. Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. JAMA Cardiology. 2021. https://jamanetwork.com/journals/jamacardiology/fullarticle/2784038

2. Faridi KF, Quispe R, Martin SS, et al. Low levels of atherogenic lipoproteins and incident atherosclerotic cardiovascular disease: A pooled cohort primary prevention study. American Heart Journal. 2026;295:107354. https://pubmed.ncbi.nlm.nih.gov/41610901/

3. Bhatia HS, Wandel S, Willeit P, et al. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2025;151(4):312-321. https://pubmed.ncbi.nlm.nih.gov/39492722/

4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. 2026;87(19):2624-2757. https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016

5. Novartis. Lp(a)HORIZON Phase III topline results for pelacarsen. September 4, 2026. https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd

6. Rikhi R, Chen H, Mirzai S, et al. The Role of Coronary Artery Calcium in Statin Eligibility Based on the American Heart Association’s PREVENT Calculator: Insights From MESA. Journal of the American College of Cardiology. 2026;88(7):739-748. https://pubmed.ncbi.nlm.nih.gov/42455102/

7. Kumar S, Shyam-Sundar V, Archbold RA, et al. Cardiovascular imaging for the detection of asymptomatic coronary artery disease: an updated systematic review of clinical practice guidelines. European Heart Journal - Imaging Methods and Practice. 2026;4(1):qyag034. https://pubmed.ncbi.nlm.nih.gov/41816017/

8. Romeo FJ, Golino M, Morello M, et al. Residual inflammatory risk and clinical outcomes after contemporary percutaneous coronary intervention: a systematic review and meta-analysis. Scientific Reports. 2026;16:8584. https://pubmed.ncbi.nlm.nih.gov/41673443/

Evidence disclosure: Source [3] was funded by Novartis; three coauthors were Novartis employees and several authors disclosed pharmaceutical-industry relationships. Source [5] is a Novartis company topline announcement, not yet a full peer-reviewed publication. Those limitations are why neither is used alone to establish the Lp(a) conclusion.